Characteristics, onset, and evolution of neurological symptoms in patients with COVID-19.
COVID-19
Neurological
SARS-CoV-2
Symptoms/manifestations
Tunisia
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
27
08
2020
accepted:
27
10
2020
pubmed:
18
11
2020
medline:
27
1
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
A wide range of neurological manifestations has been described in COVID-19. In this nationwide retrospective observational study, patients in Tunisia diagnosed with COVID-19 between the 2nd of March and the 16th of May 2020 were contacted by telephone. We collected demographic and clinical data and specified characteristics and evolution of main neurological symptoms. Of 1034 confirmed COVID-19 patients, 646 were included (mean age 42.17 years old) and 466 (72.1%) had neurological symptoms. Neurological symptoms were isolated 22.7% (n = 106). Headache was the most frequent neurological symptom (n = 279, 41.1%): mainly frontotemporal (n = 143, 51.1%) and mild or moderate (n = 165, 59.1%). When associated with fever (n = 143, 51.3%), headache was more likely to be severe and present at onset. Recovery was reported in 83.2%. Smell and taste impairment were found in 37.9% (n = 245) and 36.8% (n = 238) respectively. Among them, 65.3% (156/239) were anosmic and 63.2% (146/231) were ageusic. A complete improvement was found in 72.1% (174/240) of smell impairment and in 76.8% (179/233) of taste impairment. Myalgia (n = 241, 37.3%) and sleep disturbances (n = 241, 37.3%) were also frequent. Imported cases had more neurological symptoms (p = 0.001). In 14.5%, neurological symptoms preceded the respiratory signs (RS). RS were associated with more frequent (p = 0.006) and numerous (p < 0.001) neurological symptoms. Neurological symptoms in COVID-19 are frequent, can be isolated and present at onset. A total recovery is the most recorded outcome. RS are predictive of neurological symptoms. Studies in to virus and host genetics should be considered to understand the different phenotypes.
Sections du résumé
BACKGROUND
BACKGROUND
A wide range of neurological manifestations has been described in COVID-19.
METHODS
METHODS
In this nationwide retrospective observational study, patients in Tunisia diagnosed with COVID-19 between the 2nd of March and the 16th of May 2020 were contacted by telephone. We collected demographic and clinical data and specified characteristics and evolution of main neurological symptoms.
RESULTS
RESULTS
Of 1034 confirmed COVID-19 patients, 646 were included (mean age 42.17 years old) and 466 (72.1%) had neurological symptoms. Neurological symptoms were isolated 22.7% (n = 106). Headache was the most frequent neurological symptom (n = 279, 41.1%): mainly frontotemporal (n = 143, 51.1%) and mild or moderate (n = 165, 59.1%). When associated with fever (n = 143, 51.3%), headache was more likely to be severe and present at onset. Recovery was reported in 83.2%. Smell and taste impairment were found in 37.9% (n = 245) and 36.8% (n = 238) respectively. Among them, 65.3% (156/239) were anosmic and 63.2% (146/231) were ageusic. A complete improvement was found in 72.1% (174/240) of smell impairment and in 76.8% (179/233) of taste impairment. Myalgia (n = 241, 37.3%) and sleep disturbances (n = 241, 37.3%) were also frequent. Imported cases had more neurological symptoms (p = 0.001). In 14.5%, neurological symptoms preceded the respiratory signs (RS). RS were associated with more frequent (p = 0.006) and numerous (p < 0.001) neurological symptoms.
CONCLUSIONS
CONCLUSIONS
Neurological symptoms in COVID-19 are frequent, can be isolated and present at onset. A total recovery is the most recorded outcome. RS are predictive of neurological symptoms. Studies in to virus and host genetics should be considered to understand the different phenotypes.
Identifiants
pubmed: 33201360
doi: 10.1007/s10072-020-04866-9
pii: 10.1007/s10072-020-04866-9
pmc: PMC7670015
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
39-46Références
Tunis Med. 2020 Apr;98(4):258-260
pubmed: 32395787
Geroscience. 2020 Aug;42(4):1083-1087
pubmed: 32451846
JAMA Neurol. 2020 Aug 1;77(8):1028-1029
pubmed: 32469400
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Cell. 2020 Dec 10;183(6):1735
pubmed: 33306958
Int Forum Allergy Rhinol. 2020 Aug;10(8):944-950
pubmed: 32301284
J Neurol. 2020 Jul;267(7):1877-1879
pubmed: 32333166
Pathog Dis. 2019 Dec 1;77(9):
pubmed: 32065221
Neurology. 2020 Aug 25;95(8):e1060-e1070
pubmed: 32482845
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
Virus Genes. 2020 Dec;56(6):767-771
pubmed: 33034798
Tunis Med. 2020 Apr;98(4):261-265
pubmed: 32395788
Brain Behav Immun. 2020 Jul;87:149
pubmed: 32387508
Histopathology. 2020 Aug;77(2):186-197
pubmed: 32443177
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Curr Trop Med Rep. 2020;7(3):75-78
pubmed: 32313804
J Neurol. 2020 Aug;267(8):2196-2197
pubmed: 32458198
Neurology. 2020 Aug 4;95(5):224-225
pubmed: 32444492
IDCases. 2020 Apr 18;20:e00771
pubmed: 32313807
Neurosurgery. 2020 Aug 1;87(2):E234-E238
pubmed: 32361745
Microbiol Resour Announc. 2020 May 28;9(22):
pubmed: 32467284
J Neurol Neurosurg Psychiatry. 2020 Aug;91(8):889-891
pubmed: 32354768
Anat Rec. 2002 Feb 15;269(1):33-49
pubmed: 11891623
Int Forum Allergy Rhinol. 2020 Jul;10(7):806-813
pubmed: 32279441
Sleep Med. 2020 Jun;70:111
pubmed: 32361215
Eur J Neurol. 2020 Sep;27(9):1738-1741
pubmed: 32320508
N Engl J Med. 2020 Jun 25;382(26):2574-2576
pubmed: 32302082
Adv Otorhinolaryngol. 2006;63:125-132
pubmed: 16733337
Brain Behav Immun. 2020 Jul;87:18-22
pubmed: 32240762
J Med Virol. 2020 Oct;92(10):2165-2172
pubmed: 32410229
Clin Neurol Neurosurg. 2020 Jul;194:105921
pubmed: 32422545
Brain Behav Immun. 2020 Jul;87:115-119
pubmed: 32360439
J Peripher Nerv Syst. 2020 Jun;25(2):204-207
pubmed: 32388880
Indian J Med Res. 2020 Feb & Mar;151(2 & 3):255-260
pubmed: 32362650
J Med Virol. 2020 Oct;92(10):1793-1794
pubmed: 32311107
Eur J Neurol. 2020 Aug;27(8):1578-1587
pubmed: 32416028